Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

otential partners for the rest of world (territories outside North America and Europe) rights held by MIGENIX although the timing and completion of such a partnership(s) is uncertain at this time.

Celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): A Phase II study is currently enrolling patients to assess 600 mg celgosivir for tolerability, pharmacokinetics and viral kinetics when combined with the standard of care drugs, pegylated interferon alfa-2b plus ribavirin, as compared to the standard of care drugs alone and to 400 mg celgosivir plus the standard of care for up to 12 weeks of therapy. With 15 patients enrolled to date, it is planned that approximately six additional patients will be enrolled. In February, one of the two contract research organizations we were using to conduct this study shut down operations unexpectedly. We are in the process of transferring the planned operations at this site including patients that have been qualified for enrollment to another clinical site, and obtaining the required Institutional Review Board approval for this site. We maintain our expectation for results from the study in the third calendar quarter of 2008. MIGENIX has been and continues to be in discussions with potential partners for the further clinical development of celgosivir although the timing and completion of a partnership is uncertain at this time.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Based on positive results from a recently completed Phase II clinical study for the treatment of rosacea, our partner in this program, Cutanea Life Sciences intends to enter Phase III clinical development later this calendar year.

MX-2401 (IV lipopeptide; treatment of gram-positive bacterial infections): MX-2401 is an injectable lipopeptide being developed for the treatment of serious gram positive bacterial infections. To date, preclinical studies conduc
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... team including DESY scientists has observed tiny quantum vortices ... in the journal Science that the exotic ... nanodroplets. It is the first time that the quantum ... of what is known as superfluid helium, have been ... expectations," says Andrey Vilesov of the University of Southern ...
(Date:8/21/2014)... , August 21, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... hormone therapy, is a means of replacing ... by the body. This type of therapy ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014 ... launch of their Nutraceutical "TELO-20 for Dogs" with ... only Telomere-lengthening supplement in the world for dogs. ... of every chromosome in the body. A wealth ... leading experts in Telomere Science and Aging, including ...
(Date:8/21/2014)...  Decision Resources Group finds that the asthma ... Mexico currently faces severe ... agents, the anticipated label extension of Boehringer Ingelheim/Pfizer,s ... emerging biologics will substantially increase the competitiveness of ... inhibitors will introduce a new dynamic to the severe, ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... 26 Verenium Corporation (Nasdaq: VRNM ), ... enzyme solutions, today announced that it has renewed and ... leading global provider of heat transfer, separation and fluid ... Alfa Laval signed an agreement to jointly market enzymatic ...
... Pa. and LEUSDEN, Netherlands, Oct. 26 Molecular ... designed to increase the speed and accuracy of ... distributor Westburg BV today announced that they have ... MDI,s Detect-Ready MRSA panel in the Benelux region. ...
... 26 iDiverse announced that it has successfully modified ... lethal stresses normally encountered in the bioproduction of fuel ... to generate significantly more ethanol. "We ... and are rapidly developing a 2nd generation with yet ...
Cached Biology Technology:Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 2Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 3Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 4Molecular Detection Inc. Announces MSSA Label Expansion and Benelux Distribution Agreement for Its Detect-Ready™ MRSA Screening Test 2Molecular Detection Inc. Announces MSSA Label Expansion and Benelux Distribution Agreement for Its Detect-Ready™ MRSA Screening Test 3Molecular Detection Inc. Announces MSSA Label Expansion and Benelux Distribution Agreement for Its Detect-Ready™ MRSA Screening Test 4Molecular Detection Inc. Announces MSSA Label Expansion and Benelux Distribution Agreement for Its Detect-Ready™ MRSA Screening Test 5iDiverse Develops Stress Resistant Yeast for Producing Fuel Ethanol 2
(Date:8/21/2014)... study of American singles found that during sex ... orgasm rates. On average, men experience orgasm 85.1 ... making little difference. For women, however, orgasm occurrence ... 62.9 percent of the time during sex with ... with women,s sexual orientation, with lesbian women experiencing ...
(Date:8/21/2014)... linked to dandruff, eczema and other itchy, flaky maladies ... global reachesincluding Hawaiian coral reefs and the extreme environments ... review in the scientific journal PLOS Pathogens ... of the genus Malassezia in light of ... around the world. , University of Hawai,i at Mānoa ...
(Date:8/21/2014)... In a finding that has implications for life in ... in the solar system, LSU Associate Professor of Biological ... National Science Foundation, or NSF, this week published a ... lake that lies 800 meters (2600 feet) beneath the ... microbial ecosystems.", Given that more than 400 subglacial lakes ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4
... Philadelphia, PA, March 1, 2012 Down syndrome ... born children arising as a consequence of a chromosomal ... copies of chromosome 21, instead of the usual two. ... cognitive dysfunction that can range from mild to severe ...
... is the largest sea turtle in the world, growing ... also one of the most threatened. A major new ... zonesin the Pacific Ocean for this critically endangered species. ... practices to help reduce further deaths of this fragile ...
... A*STAR scientists have for the first time, identified that ... stem cell (ESC) self-renewal the ability of ESCs to ... for better understanding of ESC regulation and was published in ... by the team of scientists from the Institute of Medical ...
Cached Biology News:Understanding and treating the cognitive dysfunction of Down syndrome and Alzheimer's disease 2Leatherback turtle migration study identifies Pacific danger zones for endangered species 2A*STAR scientists make groundbreaking discovery on stem cell regulation 2
... The ImageXpress 5000A automated cellular imaging and ... software system designed specifically for rapid acquisition ... throughput cell-based screening. ImageXpress is fast. ... resolution (1280 x 1024 pixels), with two ...
...
... Custom Peptide Services offer a full range ... research needs. Services include: Peptide synthesis, ... Peptide synthesis, purified product (70-95% pure) ... amidation, biotinylation, fluorescein, myristylation, phosphorylation, and rhodamine) ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...
Biology Products: